Will Stryker’s MAKO Purchase Bring Disruption To The Ortho Industry?
Stryker’s adoption of MAKO’s RIO (Robotic-arm Interactive Orthopedic) system could give the global medical supplier a competitive edge over other orthopedic implant makers if the company can win converts to robotic surgery by leveraging its own experience in selling capital equipment.
You may also be interested in...
To stave off the sluggish growth in established markets, multinational medtechs not only are finding new business in countries with booming health care industries but they’re also forging new ways to serve customers. Device companies now are pushing into services, such as disease management, and angling to compete more aggressively on pricing.
Device and diagnostics companies both suffered declines in fundraising compared with previous quarters. The biggest medtech acquisition was Stryker’s $1.4 billion buyout of MAKO, while in diagnostics BioMeriux’s $450 million purchase of BioFire topped the list.
Robotic-controlled surgical tools – led by market leader MAKO Surgical Inc. – are beginning to take root in the knee surgery market, at least in partial knees. Perhaps the truest measure of the potential of this market is the growing competition that MAKO is facing: just over the past five months, Blue Belt Technologies and Stanmore Implants Worldwide received FDA approval for rival robotic surgical systems.